These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35474520)

  • 1. Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris.
    Koschitzky M; Navrazhina K; Garshick MS; Gonzalez J; Han J; Garcet S; Krueger JG
    Exp Dermatol; 2022 Sep; 31(9):1341-1351. PubMed ID: 35474520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
    Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
    J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.
    Reich K; Langley RG; Lebwohl M; Szapary P; Guzzo C; Yeilding N; Li S; Hsu MC; Griffiths CE
    Br J Dermatol; 2011 Apr; 164(4):862-72. PubMed ID: 21332467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the clinical response and changes in the expression of TNF-α and its TNFR1 and TNFR2 receptors in patients with psoriasis vulgaris treated with ustekinumab.
    Wcisło-Dziadecka DL; Grabarek B; Kruszniewska-Rajs C; Gola JM; Simka K; Mazurek U
    Adv Clin Exp Med; 2020 Feb; 29(2):235-241. PubMed ID: 32125100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis.
    Muramatsu S; Kubo R; Nishida E; Morita A
    Mod Rheumatol; 2017 Jan; 27(1):137-141. PubMed ID: 27194220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.
    Onsun N; Akaslan TÇ; Sallahoglu K; Gülcan AS; Bulut H; Yabacı A
    J Dermatolog Treat; 2022 May; 33(3):1727-1732. PubMed ID: 33704001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis.
    Chang S; Chambers CJ; Liu FT; Armstrong AW
    Dermatol Online J; 2015 Jul; 21(7):. PubMed ID: 26436967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Safety of Biologics Targeting Interleukin (IL)-12 and/or IL-23: What Does the Evidence Say?
    de Brito M; Yiu ZZN
    Am J Clin Dermatol; 2021 Sep; 22(5):587-601. PubMed ID: 34292509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
    Visvanathan S; Baum P; Vinisko R; Schmid R; Flack M; Lalovic B; Kleiner O; Fuentes-Duculan J; Garcet S; Davis JW; Grebe KM; Fine JS; Padula SJ; Krueger JG
    J Allergy Clin Immunol; 2019 Jun; 143(6):2158-2169. PubMed ID: 30578873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin and ustekinumab cotherapy alleviates induced psoriasis in rats through their antioxidant, anti-inflammatory, and antiproliferative effects.
    Mousa AM; Alhumaydhi FA; Abdellatif AAH; Abdulmonem WA; AlKhowailed MS; Alsagaby SA; Al Rugaie O; Alnuqaydan AM; Aljohani ASM; Aljasir M; Alwashmi ASS; Soliman KEA; Yosof MYR; Elsheikh SY; Babiker AY; Alsuhaibani SA; Hegazy AMS; Seleem HS
    Cutan Ocul Toxicol; 2022 Mar; 41(1):33-42. PubMed ID: 34749565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial).
    Gelfand JM; Shin DB; Alavi A; Torigian DA; Werner T; Papadopoulos M; Takeshita J; Noe MH; Dey AK; Playford MP; Mehta NN
    J Invest Dermatol; 2020 Jan; 140(1):85-93.e2. PubMed ID: 31326395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
    González-Cantero A; Ortega-Quijano D; Álvarez-Díaz N; Ballester MA; Jimenez-Gomez N; Jaen P; González-Cantero J; González-Calvin JL; Barderas MG; Shin DB; Mehta NN; Gelfand JM
    J Invest Dermatol; 2021 Oct; 141(10):2402-2411. PubMed ID: 33891953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
    Rungapiromnan W; Mason KJ; Lunt M; McElhone K; Burden AD; Rutter MK; Warren RB; Griffiths CEM; Ashcroft DM;
    J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):769-778. PubMed ID: 31633837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect Regulation and Equilibrium of p35 and p40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment.
    Zhou J; Shen JY; Liu LF; Chen JS; Dou TT; Zheng M; Cai SQ
    Med Sci Monit; 2020 Jan; 26():e920371. PubMed ID: 31910201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis.
    Umezawa Y; Hayashi M; Kikuchi S; Fukuchi O; Yanaba K; Ito T; Asahina A; Saeki H; Nakagawa H
    J Dermatol; 2015 Jul; 42(7):731-4. PubMed ID: 25959602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
    Takamura S; Takahashi A; Inoue Y; Teraki Y
    J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Efficacy of Interleukin 12/Interleukin 23 Blockade in Generalized Pustular Psoriasis Regardless of IL36RN Mutation Status.
    Arakawa A; Ruzicka T; Prinz JC
    JAMA Dermatol; 2016 Jul; 152(7):825-8. PubMed ID: 27096382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
    Dand N; Duckworth M; Baudry D; Russell A; Curtis CJ; Lee SH; Evans I; Mason KJ; Alsharqi A; Becher G; Burden AD; Goodwin RG; McKenna K; Murphy R; Perera GK; Rotarescu R; Wahie S; Wright A; Reynolds NJ; Warren RB; Griffiths CEM; Smith CH; Simpson MA; Barker JN; ; ;
    J Allergy Clin Immunol; 2019 Jun; 143(6):2120-2130. PubMed ID: 30578879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.